Prolong in survival time was not observed (Fig. S7G), which may be partly due to rapid progression of MLL-AF9-induced AML model and incomplete blockage of excessive IL-34 by the recommended dosage of Pexidartinib. Here, MLLT3 is linked to acute myeloid leukemia.